Comparison of Effectiveness of Minimum and Maximum Dose of Pantoprazole in the Treatment of Patients with Hemorrhagic Gastric Ulcer Referred to Ali-Ebn Abitaleb Hospital in Rafsanjan in 2016-2017: A Randomized Clinical Trial

Proton pump inhibitors (PPIs) have an important role in stabilizing clots caused by upper gastrointestinal bleeding. The aim of this study was performed to compare and determine the effectiveness of the minimum and maximum dose of pantoprazole in the treatment of patients with hemorrhagic gastric peptic ulcer, referred to Rafsanjan Ali ebn Abitaleb Hospital.

This randomized clinical trial was performed on 104 patients with upper gastrointestinal bleeding in Rafsanjan Ali ebn Abitaleb Hospital in 2016-2017. Patients were randomly divided into two equal groups. Group A was given a high dose of pantoprazole (80 mg) and group B was given a low dose (40 mg). For gender and age matching, the two groups were compared (p>0.05). Data were analyzed using descriptive statistics (frequency, percentage, mean and standard deviation) and inferential statistics (independent t-test, chi-square test or Fisherchr('39')s exact test). 

The mean and standard deviation of patientschr('39') age in group A were 52.96±22.79 years and in group B 52.51± 23.18 years (p=0.921). No significant difference was observed between the sexes in the two groups (p=0.823). PPI dose was not significantly associated with mortality rate, hemorrhage, hospitalization days, drop in hemoglobin, need for surgery (p>0.05).

In this study, the efficacy of high-dose pantoprazole compared with low-dose in clinical outcomes including mortality, need for surgery, hemorrhage, number of hospitalization days, and hemoglobin drop did not differ between the two groups. Therefore, for the health of patients at the optimal dose, clinical studies with a larger sample size are recommended.